Severe Alcohol Withdrawal in a Patient with Cirrhosis
A 46-year-old man with alcohol use disorder and Child-Pugh B cirrhosis is admitted with acute pancreatitis. His last drink was 36 hours ago. He has tremor, diaphoresis, and visual hallucinations; CIWA-Ar score is 22. Vital signs: heart rate 124/min, blood pressure 162/94 mmHg, respiratory rate 22/min, temperature 37.8°C. He has a history of two withdrawal seizures. Laboratory: platelets 78,000/µL, INR 1.6, total bilirubin 2.8 mg/dL, albumin 2.6 g/dL, creatinine 0.9 mg/dL, sodium 132 mmol/L, potassium 3.4 mmol/L, glucose 88 mg/dL. He is receiving IV fluids and morphine for pain. The admitting team plans to use diazepam 10 mg IV every 6 hours around the clock and asks whether that is appropriate. Nursing is concerned about oversedation because he had an episode of encephalopathy during a prior admission. No benzodiazepines have been given yet.
1. Choose a benzodiazepine strategy (agent, route, symptom-triggered versus fixed) and justify it in cirrhosis.
Read the worked answer
Use symptom-triggered lorazepam rather than fixed-dose diazepam. Lorazepam undergoes glucuronidation and has no active hepatic metabolites, so it is less affected by cirrhosis than diazepam or chlordiazepoxide, which undergo hepatic oxidation and generate long-lived active metabolites that can accumulate and worsen encephalopathy. The route should be IV because the patient is vomiting and has a high CIWA score; oral is unreliable. Start with lorazepam 2-4 mg IV and reassess every 15-30 minutes, using the CIWA-Ar to guide repeat doses. Symptom-triggered therapy avoids oversedation and is associated with less total benzodiazepine exposure than around-the-clock dosing, but this patient has a history of withdrawal seizures and a CIWA of 22, so he needs close monitoring in a setting where rapid escalation is possible. If he develops delirium tremens or seizures, use higher doses and consider a continuous infusion. Do not use diazepam 10 mg every 6 hours as a fixed regimen in Child-Pugh B cirrhosis; the active metabolite desmethyldiazepam can accumulate for days and confound the neurologic examination.
2. Address the role of phenobarbital and dexmedetomidine in benzodiazepine-refractory withdrawal, with monitoring.
Read the worked answer
Phenobarbital is an adjunct for benzodiazepine-refractory withdrawal because it enhances GABA-A receptor activity at a different site and can reduce benzodiazepine requirements. It is not a first-line substitute in a patient with cirrhosis, but a single weight-based dose or a small protocolized load can be considered in an ICU setting with continuous pulse oximetry, capnography, and frequent sedation scales. The main risk is respiratory depression and oversedation, especially with concurrent opioids for pancreatitis; the morphine should be minimized or monitored closely. Phenobarbital is hepatically metabolized, so cirrhosis prolongs its effect. Dexmedetomidine is an alpha-2 agonist that can control autonomic hyperactivity and agitation, but it does not prevent withdrawal seizures and should not be used as monotherapy. It causes bradycardia and hypotension, so monitor heart rate and blood pressure. In this patient, the priority is adequate benzodiazepine dosing with lorazepam; if he remains agitated or requires escalating doses, add phenobarbital or dexmedetomidine only with ICU-level monitoring and a clear airway plan.
3. Outline prophylaxis and monitoring for Wernicke encephalopathy and seizures, including thiamine and glucose.
Read the worked answer
Give thiamine before or with glucose. For a patient with alcohol use disorder and poor nutrition who is at risk for Wernicke encephalopathy, use high-dose IV thiamine, such as 500 mg IV every 8 hours for 2-3 days, then 250 mg IV daily for 3-5 days, followed by oral thiamine. This is more than the traditional 100 mg dose and is appropriate because his intake has been poor and he has cirrhosis. Check glucose; if hypoglycemia is present, give glucose after thiamine, not instead of it. Monitor for confusion, ophthalmoplegia, nystagmus, and ataxia, which may be masked by sedatives. For seizures, lorazepam is the first-line treatment; phenytoin is not effective for alcohol withdrawal seizures. Keep electrolytes corrected, especially magnesium and potassium, because hypomagnesemia lowers the seizure threshold and impairs thiamine utilization. Monitor CIWA-Ar, vital signs, oxygen saturation, and level of consciousness. A falling level of consciousness should prompt evaluation for hepatic encephalopathy, hypoglycemia, subdural hematoma, and oversedation, not simply more sedation.